This application requests support to continue our exploration of beta-peptide structure and biologic function. We build herein on two of the most exciting and impacting discoveries of the first funding cycle: (1) that carefully designed beta-peptides effectively mimic ?- helices and function as protein interaction inhibitors, with properties that are easily improved by combinatorial methods;and (2) that beta-peptides can be engineered to traverse the plasma membrane and retain biologic function in the cytosol, without the addition of a large "octa-arginine" tag, facilitating their application to intracellular targets. Thus, the Specific Aims of this application are to first (Aim 1) move away from "proof-of- principle" targets, and design beta-peptide ligands for two well-validated drug targets that could benefit from the unique combination of properties embodied by a beta-peptide: the GLP-1 receptor (GLP-1R), a target of the antidiabetes drug Byetta", and the ErbB2 receptor, a target of the mAb Herceptin". We also describe beta-peptides that either inhibit or activate CXCR4 and CCR5 chemokine receptors from within the plasma membrane.
In Aim 2, we described experiments to systematically optimize and exploit cell- permeable beta-peptides as a first step toward broadening their applicability to cytosolic targets. The fact that beta-peptides are immune to proteolytic degradation makes them uniquely capable of reporting on the myriad pathways by which peptides achieve uptake and traffic within the cell once they do.
Protein-protein interactions on the cell surface or in the cytosol are grossly underexploited in human medicine. beta-peptides possess unique advantages as inhibitors of these interactions. This proposal explores these advantages in the context of diseases as diverse as type 2 diabetes, cancer, osteoporosis, and hypoparathyrodism.
|Miller, Jonathan P; Melicher, Michael S; Schepartz, Alanna (2014) Positive allostery in metal ion binding by a cooperatively folded ?-peptide bundle. J Am Chem Soc 136:14726-9|
|Qian, Ziqing; LaRochelle, Jonathan R; Jiang, Bisheng et al. (2014) Early endosomal escape of a cyclic cell-penetrating peptide allows effective cytosolic cargo delivery. Biochemistry 53:4034-46|
|Denton, Elizabeth V; Craig, Cody J; Pongratz, Rebecca L et al. (2013) A ?-peptide agonist of the GLP-1 receptor, a class B GPCR. Org Lett 15:5318-21|
|Bautista, Arjel D; Appelbaum, Jacob S; Craig, Cody J et al. (2010) Bridged beta(3)-peptide inhibitors of p53-hDM2 complexation: correlation between affinity and cell permeability. J Am Chem Soc 132:2904-6|
|Molski, Matthew A; Goodman, Jessica L; Craig, Cody J et al. (2010) Beta-peptide bundles with fluorous cores. J Am Chem Soc 132:3658-9|
|Harker, Elizabeth A; Daniels, Douglas S; Guarracino, Danielle A et al. (2009) Beta-peptides with improved affinity for hDM2 and hDMX. Bioorg Med Chem 17:2038-46|
|Michel, Julien; Harker, Elizabeth A; Tirado-Rives, Julian et al. (2009) In Silico Improvement of beta3-peptide inhibitors of p53 x hDM2 and p53 x hDMX. J Am Chem Soc 131:6356-7|
|Bautista, Arjel D; Stephens, Olen M; Wang, Ligong et al. (2009) Identification of a beta3-peptide HIV fusion inhibitor with improved potency in live cells. Bioorg Med Chem Lett 19:3736-8|
|Harker, Elizabeth A; Schepartz, Alanna (2009) Cell-permeable beta-peptide inhibitors of p53/hDM2 complexation. Chembiochem 10:990-3|
|Goodman, Jessica L; Molski, Matthew A; Qiu, Jade et al. (2008) Tetrameric beta(3)-peptide bundles. Chembiochem 9:1576-8|
Showing the most recent 10 out of 19 publications